Trials / Not Yet Recruiting
Not Yet RecruitingNCT06869174
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pucotenlimab in Combination with MRG002 in Treating HER2-positive Cancer of Unknown Primary
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Zhiguo Luo, MD, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pucotenlimab combined with MRG002 | Pucotenlimab 200mg iv d1, Q3W MRG002 2.2mg/kg d1, Q3W |
Timeline
- Start date
- 2025-03-08
- Primary completion
- 2027-03-08
- Completion
- 2028-08-08
- First posted
- 2025-03-11
- Last updated
- 2025-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06869174. Inclusion in this directory is not an endorsement.